Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE-HeFH: AZD0780 in Heterozygous Familial Hypercholesterolaemia
NCT07000136Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing AZD0780 with Placebo (2 arms). Primary endpoint: Relative change in Low-Density Lipoprotein Cholesterol at 12 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
laroprovstat
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT07000136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000136.